Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications

Overview

Journal Brain Sci

Publisher MDPI

Date 2025 Feb 26

PMID 40002450

Authors

Francesco Weiss

Anna Magnesa

Matteo Gambini

Riccardo Gurrieri

Eric Annuzzi

Camilla Elefante

Giulio Perugi

Donatella Marazziti

Affiliations

Soon will be listed here.

Abstract

: Psychedelics are increasingly recognized as a promising and innovative treatment strategy for several mental disorders. However, there is still a lively controversy in the medical community as regards the rationale of their employment, specifically their indications and potential dangers. : A comprehensive literature search on "MEDLINE/PubMed" and "Web of Science" was performed from inception to 26 June 2024, cross-checking the obtained references. We included all studies, i.e., both clinical and preclinical, that supplied original data. : We initially obtained a total of 1083 entries, 813 from MEDLINE/PubMed and 270 from Web of Science. After duplicate elimination, 903 underwent systematic literature selection. Primary abstract screening yielded a total of 572 candidates for eligibility assessment and excluded 331 entries on formal grounds. Eligibility assessment led to the exclusion of 501 titles. Finally, a total of 70 articles were included in this review. : Preclinical evidence from genetic expression, histology and behavioral studies is soundly consistent with psychedelics possessing neuroplasticity-inducing properties. Despite methodological difficulties, clinical evidence seems to be inferentially in agreement with preclinical findings. However, it is still unclear whether the "neuroplastic boost" induced by classic psychedelics might be dissociable from the psychodysleptic effects, thereby reducing the psychopathological hazards implied by these compounds. Moreover, the fact that the so-called "relaxation of priors" should be unconditionally beneficial appears debatable, and further research should clarify the possible indications and contraindications of psychedelic psychoplastogens within a precision medicine perspective.

References

Zarate Jr C, Singh J, Carlson P, Brutsche N, Ameli R, Luckenbaugh D . A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006; 63(8):856-64. DOI: 10.1001/archpsyc.63.8.856. View

Sabanovic M, Lazari A, Blanco-Pozo M, Tisca C, Tachrount M, Martins-Bach A . Lasting dynamic effects of the psychedelic 2,5-dimethoxy-4-iodoamphetamine ((±)-DOI) on cognitive flexibility. Mol Psychiatry. 2024; 29(6):1810-1823. PMC: 11371652. DOI: 10.1038/s41380-024-02439-2. View

Gonul A, Akdeniz F, Taneli F, Donat O, Eker C, Vahip S . Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci. 2005; 255(6):381-6. DOI: 10.1007/s00406-005-0578-6. View

Olson D . Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics. J Exp Neurosci. 2018; 12:1179069518800508. PMC: 6149016. DOI: 10.1177/1179069518800508. View

Nichols C, Garcia E, Sanders-Bush E . Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration. Brain Res Mol Brain Res. 2003; 111(1-2):182-8. DOI: 10.1016/s0169-328x(03)00029-9. View

Ly C, Greb A, Cameron L, Wong J, Barragan E, Wilson P . Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018; 23(11):3170-3182. PMC: 6082376. DOI: 10.1016/j.celrep.2018.05.022. View

Inserra A, Campanale A, Cheishvili D, Dymov S, Wong A, Marcal N . Modulation of DNA methylation and protein expression in the prefrontal cortex by repeated administration of D-lysergic acid diethylamide (LSD): Impact on neurotropic, neurotrophic, and neuroplasticity signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2022; 119:110594. DOI: 10.1016/j.pnpbp.2022.110594. View

Berthoux C, Barre A, Bockaert J, Marin P, Becamel C . Sustained Activation of Postsynaptic 5-HT2A Receptors Gates Plasticity at Prefrontal Cortex Synapses. Cereb Cortex. 2018; 29(4):1659-1669. DOI: 10.1093/cercor/bhy064. View

Kocarova R, Horacek J, Carhart-Harris R . Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?. Front Psychiatry. 2021; 12:661233. PMC: 8327748. DOI: 10.3389/fpsyt.2021.661233. View

10.

OLeary O, Wu X, Castren E . Chronic fluoxetine treatment increases expression of synaptic proteins in the hippocampus of the ovariectomized rat: role of BDNF signalling. Psychoneuroendocrinology. 2008; 34(3):367-81. DOI: 10.1016/j.psyneuen.2008.09.015. View

11.

Barrett F, Doss M, Sepeda N, Pekar J, Griffiths R . Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020; 10(1):2214. PMC: 7010702. DOI: 10.1038/s41598-020-59282-y. View

12.

Castren E . Neurotrophic effects of antidepressant drugs. Curr Opin Pharmacol. 2004; 4(1):58-64. DOI: 10.1016/j.coph.2003.10.004. View

13.

Kyrios M, Nelson B, Ahern C, Fuchs T, Parnas J . The Self in Psychopathology. Psychopathology. 2015; 48(5):275-7. DOI: 10.1159/000438876. View

14.

Rijsketic D, Casey A, Barbosa D, Zhang X, Hietamies T, Ramirez-Ovalle G . UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice. Neuropsychopharmacology. 2023; 48(12):1798-1807. PMC: 10579391. DOI: 10.1038/s41386-023-01613-4. View

15.

Timmermann C, Spriggs M, Kaelen M, Leech R, Nutt D, Moran R . LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm. Neuropharmacology. 2017; 142:251-262. DOI: 10.1016/j.neuropharm.2017.10.039. View

16.

Jaffe R, Novakovic V, Peselow E . Scopolamine as an antidepressant: a systematic review. Clin Neuropharmacol. 2013; 36(1):24-6. DOI: 10.1097/WNF.0b013e318278b703. View

17.

Bremner J, Narayan M, Anderson E, Staib L, Miller H, Charney D . Hippocampal volume reduction in major depression. Am J Psychiatry. 2000; 157(1):115-8. DOI: 10.1176/ajp.157.1.115. View

18.

Carhart-Harris R, Chandaria S, Erritzoe D, Gazzaley A, Girn M, Kettner H . Canalization and plasticity in psychopathology. Neuropharmacology. 2022; 226:109398. DOI: 10.1016/j.neuropharm.2022.109398. View

19.

Brouwer A, Carhart-Harris R . Pivotal mental states. J Psychopharmacol. 2020; 35(4):319-352. PMC: 8054165. DOI: 10.1177/0269881120959637. View

20.

Bahrami S, Drablos F . Gene regulation in the immediate-early response process. Adv Biol Regul. 2016; 62:37-49. DOI: 10.1016/j.jbior.2016.05.001. View